DongKook Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	954,164	926,884	812,166	730,994	661,647	594,193
Other Revenue	-	-	-	-	-0	-
Revenue	954,164	926,884	812,166	730,994	661,647	594,193
Revenue Growth (YoY)	13.71%	14.12%	11.10%	10.48%	11.35%	6.28%
Cost of Revenue	432,017	425,655	364,598	320,443	281,999	244,272
Gross Profit	522,147	501,228	447,568	410,551	379,648	349,921
Selling, General & Admin	375,310	359,001	328,148	310,542	277,684	257,570
Research & Development	34,552	32,820	30,325	25,456	21,818	24,691
Amortization of Goodwill & Intangibles	1,730	1,535	771.45	124.19	92.39	114.47
Other Operating Expenses	1,596	1,607	1,343	1,278	1,350	887.7
Operating Expenses	423,615	404,754	367,703	343,677	306,107	286,702
Operating Income	98,533	96,474	79,865	66,873	73,541	63,219
Interest Expense	-1,800	-2,077	-4,497	-5,868	-4,320	-2,883
Interest & Investment Income	5,666	5,575	6,335	5,258	2,903	2,454
Earnings From Equity Investments	-1,948	-3,689	2,553	-896.71	1,122	1,031
Currency Exchange Gain (Loss)	91.35	-1,071	1,840	-65.38	708.54	2,657
Other Non Operating Income (Expenses)	-1,196	-1,633	-6,790	596.82	-603.97	932.71
EBT Excluding Unusual Items	99,345	93,579	79,305	65,898	73,350	67,411
Gain (Loss) on Sale of Investments	-3,796	-4,723	3,284	-5,814	-5,337	1,376
Gain (Loss) on Sale of Assets	5,470	5,580	2,148	752.89	618.82	966.3
Asset Writedown	-966.19	-1,848	-	-	-	-
Pretax Income	100,053	92,588	84,738	60,838	68,632	69,754
Income Tax Expense	17,778	18,655	22,401	11,966	13,876	16,837
Earnings From Continuing Operations	82,275	73,933	62,336	48,871	54,757	52,916
Minority Interest in Earnings	-7,757	-7,912	-1,117	-1,696	-1,861	-2,571
Net Income	74,518	66,020	61,219	47,175	52,896	50,345
Preferred Dividends & Other Adjustments	-	-	449.93	399.85	-	-
Net Income to Common	74,518	66,020	60,769	46,775	52,896	50,345
Net Income Growth	28.50%	7.84%	29.77%	-10.81%	5.07%	-9.98%
Shares Outstanding (Basic)	45	44	44	44	44	44
Shares Outstanding (Diluted)	45	45	45	45	45	45
Shares Change (YoY)	0.43%	0.05%	0.01%	0.02%	0.01%	-
EPS (Basic)	1669.79	1486.80	1382.16	1064.03	1203.46	1145.56
EPS (Diluted)	1659.93	1475.00	1368.41	1054.64	1183.00	1126.00
EPS Growth	27.96%	7.79%	29.75%	-10.85%	5.06%	-9.99%
Free Cash Flow	29,313	26,046	48,800	7,616	-7,005	-6,352
Free Cash Flow Per Share	652.99	581.92	1090.81	170.27	-156.64	-142.04
Dividend Per Share	200.000	200.000	-	-	-	-
Gross Margin	54.72%	54.08%	55.11%	56.16%	57.38%	58.89%
Operating Margin	10.33%	10.41%	9.83%	9.15%	11.12%	10.64%
Profit Margin	7.81%	7.12%	7.48%	6.40%	7.99%	8.47%
Free Cash Flow Margin	3.07%	2.81%	6.01%	1.04%	-1.06%	-1.07%
EBITDA	131,110	128,186	108,327	87,971	92,728	80,577
EBITDA Margin	13.74%	13.83%	13.34%	12.03%	14.02%	13.56%
D&A For EBITDA	32,578	31,712	28,462	21,098	19,187	17,358
EBIT	98,533	96,474	79,865	66,873	73,541	63,219
EBIT Margin	10.33%	10.41%	9.83%	9.15%	11.12%	10.64%
Effective Tax Rate	17.77%	20.15%	26.44%	19.67%	20.22%	24.14%
Advertising Expenses	-	91,121	83,743	76,804	66,472	67,064